Will Camzyos Strengthen BMY's Cardiovascular Portfolio?

Bristol Myers Squibb (BMY) showcased robust growth in its cardiovascular portfolio, with Q2 Eliquis sales rising 6% to $3.7 billion and Camzyos surging 86% to $260 million, driven by strong demand and global launches. While Eliquis faces generic competition later this decade, Camzyos's rapid expansion is expected to mitigate this slowdown, supported by upcoming readouts for pipeline candidate milvexian. Despite these operational strengths and recent upward revisions to 2025/2026 EPS estimates, BMY shares have declined 16.5% year-to-date and trade at a significant discount to the large-cap pharma industry.

Analysis

Bristol Myers Squibb's cardiovascular franchise shows a mixed profile of current strength against future headwinds. The company's top-line contributor, Eliquis, continues to grow, with sales rising 6% to $3.7 billion in the second quarter, but it faces a significant patent cliff from generic competition later this decade. To counter this, BMY is relying on its newer drug, Camzyos, which demonstrated exceptional momentum with an 86% sales surge to $260 million, fueled by strong U.S. demand. However, this growth faces a potential challenge from Cytokinetics' competing drug, aficamten, which has a target action date of December 26, 2025. The company's pipeline, particularly the candidate milvexian with key readouts expected next year, represents a critical long-term catalyst. Despite positive operational data and upward revisions to 2025 and 2026 earnings estimates, BMY's stock has underperformed its industry peers, declining 16.5% year-to-date and trading at a significant discount with a forward P/E ratio of 7.59x compared to the industry's 14.79x, suggesting the market is heavily weighing the long-term risks.

Key Decisions for Investors

• Given the stock's 16.5% year-to-date decline and discounted valuation, investors may consider the current price a potential entry point, but must be prepared for volatility associated with the long-term Eliquis patent expiration.
• Monitor the clinical trial readouts for the pipeline candidate milvexian in 2025, as positive data could act as a significant catalyst to rerate the stock and improve the long-term growth outlook.
• Investors should track the regulatory progress of Cytokinetics' aficamten, as its potential approval in late 2025 and launch in 2026 represents the most direct competitive threat to Camzyos's growth trajectory.
• Closely watch Camzyos's quarterly sales figures and new patient starts to gauge if its high-growth momentum can be sustained, as it is a key component in offsetting the eventual revenue decline from Eliquis.